I promise

"I promise, Suzy... Even if it takes the rest of my life." - Nancy G. Brinker, founder of Susan G. Komen for the Cure

What is Triple Negative Breast Cancer?

WHAT IS TRIPLE NEGATIVE BREAST CANCER?

Just in recent years, Triple Negative Breast Cancer has sparked interest in the news where instead of calling the tumor as ER-negative, PR-negative, and HER2-negative; researchers began using the shorthand term, "Triple Negative," dubbed the "new type" type of cancer. Being Triple Negative, you don't have a targeted therapy and that your only treatment option is chemotherapy.

Triple Negative is seen in about 15% of all breast cancers. Triple Negative is a very aggressive cancer that tends to strike younger women, pre-menopause, especially among African-American women and women who have BRCA1 mutations. The tumor tends to be fast growing and is less likely to show up on an annual mammogram. TN is more likely to metastasis early on; has a high rate of recurrence in the first 2-3 years from diagnosis and has a poorer prognosis than other types of breast cancer due to lack of specific, targeted treatment for TNBC.

Carpe diem

Seize Each new Day with Renewed Strength,
Believe in Yourself, Go forward with
Courage and faith
to face whatever Tomorrow may bring.

Chicks For Charity motto:

Enjoy life. Laugh a lot.
Work hard. Play hard.
Be thankful for our blessings.
Share the wisdom. Give back
.

Sunday, November 13, 2011

My Cancer Treatment Team: Dr. Candilee Butler, Dr. Iman Mohamed And Dr. Jeffrey Forquer

Dr. Candilee Butler, MD- My Breast Care Surgeon

Medical School:

University Of Toledo College Of Medicine
Toledo, OH, United States
Graduated: 1982 

Residency Hospital:

Med College Ohio
Toledo, OH, USA
Year completed: 1988


Internship Hospital:

Med College Ohio
Toledo, OH, US
Year completed: 1983 
Dr. Candilee Butler MD practices general surgery in Toledo, OH. Dr. Butler graduated with an MD 29 years ago.
Specialties:
  • General Surgery- Board Certified 
Most Common Procedures: 
  • Breast Tissue Expander Insertion
  • Mastectomy
  • Lymph Node Biopsy
  • Lymph Node Removal
  • Breast Lesion Removal
  • Diagnostic Breast Procedure

Please call Candilee Butler, MD at (419) 841-6600 to schedule an appointment in Toledo, OH or to get more information.



Dr Iman Mohamed, MD- My Medical Oncologist 
University of Toledo Medical Center Toledo, OH- Current position
Internist, Medical Oncologist- Board Certified
Professor, Medicine
Chief, Division of Hematology/Oncology
Medical Director, Breast Center
Medical Director of the Comprehensive Breast Center at the UTMC Cancer Institute



Medical School:
Kuwait University
Health Sciences Centre
Faculty of Medicine
Satfat, Kuwait
Graduated 1985

Residency Hospital:
St. Joseph Mercy Hospital
Pontiac, MI
Internal Medicine
Year completed: 1993

Fellowship Hospital:
William Beaumont Hospital
Royal Oak, Michigan
Oncology
Year completed: 1993

Dr. Iman Mohamed, MD practices Hematolgy in Toledo, OH. Dr Mohamed graduated with a MD 26 years ago.

Specialties:
. Hematology
. Oncology
Ohio licensed since 1999
Special Interests:
Clinical: Breast Cancer/Genetic Counseling
Research: Novel Therapy for Metastatic Breast Cancer and Locally Advanced Breast Cancer

Please call Dr. Iman Mohamed, MD at (419) 383-6644 to schedule an appointment in Toledo, OH or for more information.


                       My Chemotherapy Nurses
video




Michelle Bragazzi, RN, BS
My "Clodronate" Study Coordinator

University of Toledo Medical Center, Toledo,OH-
Jacobson Center for Clinical Research
Position: Oncology Research Coordinator
michelle.bragazzi@utoledo.edu
Phone: 419-383-6962

My Clinical Study:
Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer

The purpose of this study is to compare overall survival in patients receiving clodronate versus ibandronate versus zoledronic acid as adjuvant therapy for breast cancer in an attempt to prevent bone metastasis.  Bisphosphonates are a diverse group of compounds, which have profound effects on bone mineralization and resorption.  This study was for a confirmed diagnosis of primary invasive adenocarcinoma of the breast (Stage I, II, III) with no evidence of metastatic disease, primary disease within the breast must be resected, either with mastectomy or breast sparing surgery, receiving standard (systemic) adjuvant therapy for breast cancer, at least 18 years of age and female. This study is ongoing but is now closed to participants. 
Principal Investigator:  Iman Mohamed, M.D.



Dr Jeffrey Alan Forquer, MD- My Radiation Oncologist

Medical School:
The Ohio State University College of Medicine
Columbus, OH
Year completed 2004


Internship: Riverside Methodist Hospital


Residency: Indiana University
Dr. Jeffrey Alan Forquer MD practices radiology in Maumee OH., Sylvania OH., Oregon OH. and Toledo OH. Dr. Forquer graduated with an MD 7 years ago.

Specialties:
. Radiology- Board Certified
. Radiation of Oncology
Ohio Licensed

Please contact Dr. Jeffrey Alan Forquer, MD at (419) 824-1952 to schedule an appointment in the Toledo, OH area or for more information.



No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Total Pageviews

Click to help fund mammograms for the uninsured

The Breast Cancer Site

Click to join me in support group

Inspire health and wellness support groups

Triple Negative Breast Cancer Foundation

Triple Negative Breast Cancer Foundation
"click image to link"

"Click image to link"

The SCAR Project

The SCAR Project
"Click image to link"

CRABBYCARDS.COM

CRABBYCARDS.COM
"Click image to link"

Breast Cancer Awareness Body Painting Project

Breast Cancer Awareness Body Painting Project
"Click image to link"